alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<LEGEND>
                              THIS SCHEDULE CONTAINS SUMMARY FINANCIAL 
                              INFORMATION EXTRACTED FROM THE COMPANY'S FINANCIAL
                              STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY
                              REFERENCE TO SUCH FINANCIAL STATEMENTS INCLUDED
                              AS A PART OF THIS FORM 20-F
</LEGEND>
[ARTICLE]                     5
<MULTIPLIER>                                     1,000
<CURRENCY>                                           $
       
<S>                             <C>
<PERIOD-TYPE>                                     Year
<FISCAL-YEAR-END>                          Dec-31-1997
<PERIOD-START>                             Jan-01-1997
<PERIOD-END>                               Dec-31-1997
<EXCHANGE-RATE>                                      1
<CASH>                                           1,234
<SECURITIES>                                         0
<RECEIVABLES>                                    8,266
<ALLOWANCES>                                       540
<INVENTORY>                                      2,252
<CURRENT-ASSETS>                                11,212
<PP&E>                                           2,444
<DEPRECIATION>                                     803
<TOTAL-ASSETS>                                  13,783
<CURRENT-LIABILITIES>                            6,538
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         2,729
<OTHER-SE>                                       3,056
<TOTAL-LIABILITY-AND-EQUITY>                    13,783
<SALES>                                         21,959
<TOTAL-REVENUES>                                21,959
<CGS>                                           11,311
<TOTAL-COSTS>                                    9,202
<OTHER-EXPENSES>                                     8
<LOSS-PROVISION>                                   540
<INTEREST-EXPENSE>                                 320
<INCOME-PRETAX>                                    578
<INCOME-TAX>                                        67
<INCOME-CONTINUING>                                511
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                     26
<CHANGES>                                            0
<NET-INCOME>                                       485
<EPS-PRIMARY>                                     0.07
<EPS-DILUTED>                                     0.07
        

</TABLE>
```

[Federal Register Volume 75, Number 37 (Thursday, February 25, 2010)]
[Notices]
[Page 8693]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-3802]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER10-711-000]

Respond Power LLC; Supplemental Notice That Initial Market-Based 
Rate Filing Includes Request for Blanket Section 204 Authorization

February 17, 2010.
    This is a supplemental notice in the above-referenced proceeding of 
Respond Power LLC's application for market-based rate authority, with 
an accompanying rate tariff, noting that such application includes a 
request for blanket authorization, under 18 CFR part 34, of future 
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the 
Federal Energy Regulatory Commission, 888 First Street, NE., 
Washington, DC 20426, in accordance with Rules 211 and 214 of the 
Commission's Rules of Practice and Procedure (18 CFR 385.211 and 
385.214). Anyone filing a motion to intervene or protest must serve a 
copy of that document on the Applicant.
    Notice is hereby given that the deadline for filing protests with 
regard to the applicant's request for blanket authorization, under 18 
CFR part 34, of future issuances of securities and assumptions of 
liability, is March 9, 2010.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with Internet 
access who will eFile a document and/or be listed as a contact for an 
intervenor must create and validate an eRegistration account using the 
eRegistration link. Select the eFiling link to log on and submit the 
intervention or protests.
    Persons unable to file electronically should submit an original and 
14 copies of the intervention or protest to the Federal Energy 
Regulatory Commission, 888 First Street, NE., Washington, DC 20426.
    The filings in the above-referenced proceeding are accessible in 
the Commission's eLibrary system by clicking on the appropriate link in 
the above list. They are also available for review in the Commission's 
Public Reference Room in Washington, DC. There is an eSubscription link 
on the Web site that enables subscribers to receive e-mail notification 
when a document is added to a subscribed docket(s). For assistance with 
any FERC Online service, please e-mail [email protected], or 
call (866) 208-3676 (toll free). For TTY, call (202) 502-8659.

Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2010-3802 Filed 2-24-10; 8:45 am]
BILLING CODE 6717-01-P
```
U. S. Department of Homeland Security

 

 Office for Domestic Preparedness

 

 Washington, D.C. 20531

ODP Information Bulletin #69

 March 25, 2003

TO: All State Administrative Agency Heads

All State Administrative Agency Points of Contact

FROM: Andrew T. Mitchell

Acting Director

SUBJECT: Release of Homeland Security Exercise and Evaluation Program - Volume I:

Overview and Doctrine

The Office for Domestic Preparedness (ODP) is pleased to announce the release of the first in a

series of documents on its Homeland Security Exercise and Evaluation Program (HSEEP). The

HSEEP is a national exercise program of financial and direct support to assist state and local

governments with the development and implementation of a state exercise and evaluation

program to assess and enhance domestic preparedness. 

The HSEEP series is designed to provide guidance on the design, conduct, and evaluation of

terrorism threat- and performance-based exercises. This document, Homeland Security Exercise

and Evaluation Program - Volume I: Overview and Doctrine, provides the state and local

homeland security community with: ODP’s exercise and evaluation doctrine; a uniform approach

for exercise design, development, conduct, and evaluation; and an exercise design and

implementation process. Subsequent volumes of the HSEEP manuals will provide additional

guidance on the design, development, conduct and evaluation of exercises.

The document is currently available on ODP’s webpage at www.ojp.usdoj.gov/odp. We are

having the document printed and will send multiple copies to you shortly. Other documents in

the series will be available in the coming months.
§ 21.54 Amended or disputed records received from other agencies. Whenever the Food and Drug Administration is notified that a record that it received from another agency was amended or is the subject of a statement of disagreement, the Food and Drug Administration shall: ( a ) Discard the record, or clearly note the amendment or the fact of disagreement in its copy of the record, and
( b ) Refer persons who subsequently request the record to the agency that provided it.
( c ) If an accounting was made under § 21.71 (d) and (e) of the disclosure of the record under § 21.71(a), inform all previous recipients of the record about the amendment or provide to them the statement of disagreement and the agency statement, if any.
EXHIBIT 21.1

                      SUBSIDIARIES AS OF DECEMBER 31, 2000

                                        Jurisdiction of            Percent
      Name                               Incorporation            Ownership
      ----                               -------------            ---------
GolfWeb                                  California                  100%
Sports.com Limited                       United Kingdom             46.3%
Commissioner.com, Inc.                   New York                    100%
VegasInsider, Inc.                       Delaware                    100%
Las Vegas Sports Consultants, Inc.       Nevada                      100%*
MVP.com Sports, Inc.**                   Delaware                    100%

*  Las Vegas Sports Consultants, Inc. is 100% owned by VegasInsider, Inc.
**  MVP.com Sports, Inc. was incorporated in January 2001
#### § 357.203 Definition.

As used in this subpart:

*Cholecystokinetic drug product.* A drug product that causes contraction of the gallbladder and is used during the course of diagnostic gallbladder studies (cholecystography).

[48 FR 27005, June 10, 1983]
<PAGE>

                          NCC EXPORT SYSTEMS 1995 LTD.
                               20 Shenkar Street
                           Beit Hatikva 49130, Israel





                                                           January 29, 1997





PaperClip Software, Inc.
Three University Plaza
Hackensack, NJ    07601
ATTN:  William Weiss

Dear Mr. Weiss:

         Reference is made to (i) that certain Reschedule Agreement between NCC
Export Systems 1995 LTD. ("us" or "we") and PaperClip Imaging Software, Inc.
(n/k/a PaperClip Software, Inc., "you"), dated as of the 21st day of October,
1996 (the "Reschedule Agreement") and (ii) that certain Security Agreement
between you as Pledgor and us as Secured Party, dated as of the 21st day of
October, 1996 (the "Security Agreement").

         We are confirming herewith that we are in receipt of $65,634.50, which
is the full amount owed to us by you pursuant to the Reschedule Agreement.

         In consideration of the above mentioned payment, we hereby terminate
each of the Reschedule Agreement and the Security Agreement. We shall execute
all documents reasonably necessary to evidence the termination of the liens and
security interests granted to us pursuant to the Reschedule Agreement and the
Security Agreement.

                                       NCC EXPORT SYSTEMS 1995 LTD.


                                       By: /s/ Moshe Attias
                                          --------------------------------
                                          Name: Moshe Attias
                                          Title: Vice President for Finances
###### Editorial Note on Part 17

#### Editorial Note:

Nomenclature changes to part 17 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

#### § 17.54 Deposit in the Treasury of the United States.

All amounts assessed pursuant to this part shall be delivered to the Director, Division of Financial Management (HFA-100), Food and Drug Administration, rm. 11-61, 5600 Fishers Lane, Rockville, MD 20857, and shall be deposited as miscellaneous receipts in the Treasury of the United States.
EXHIBIT 23.1

CONSENT OF INDEPENDENT

REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders

of The Southern Banc Company,
Inc.

We consent to the incorporation by reference in the registration statement No. 333-3546 on Form S-8 of The Southern Banc Company, Inc. of our
report dated August 18, 2006 with respect to the consolidated statements of financial condition of The Southern Banc Company, Inc. as of June 30, 2006 and 2005, and the related consolidated statements of income, stockholders equity,
and cash flows for the years then ended, which report appears in the June 30, 2006 annual report on Form 10-KSB of The Southern Banc Company, Inc.



|                                         
|-----------------------------------------
|/s/ Barfield, Murphy, Shank & Smith, P.C.
|                                         
|Birmingham, Alabama                      
|September 28, 2006                       



89
<PAGE>   1

EXHIBIT 10.5                THIRD AMENDMENT AGREEMENT

THIS AGREEMENT is dated for reference the 12th day of February, 1999

AMONG:

                ACCEL FINANCIAL GROUP LTD., a corporation incorporated under the
                laws of Alberta

                (the "Corporation")

AND:

                802685 ALBERTA LTD., a corporation incorporated under the laws
                of Alberta

                ("Holdco")

AND:

                T&W FINANCIAL SERVICES COMPANY L.L.C., a limited liability
                company incorporated under the laws of the State of Washington

                ("T&W")

WHEREAS:

(A)     The parties hereto are parties to an amalgamation agreement dated
November 6, 1998, as amended by an amendment agreement dated December 7, 1998,
and a second amendment agreement dated January 29, 1999 (collectively, the
Amalgamation Agreement); and

(B)     The parties wish to enter into this Agreement to amend the Amalgamation
Agreement in order to make effective certain amendments that they have agreed
to.

THEREFORE THIS AGREEMENT WITNESSES that the parties agree as follows:

1.      The Amalgamation Amendment Agreement is hereby amended by deleting
Section 18(g) and replacing it with the following provision:

        "(g)    not later than the second Business Day immediately before the
        Effective Date, Holdco secures a firm financing commitment sufficient to
        permit it to complete the Amalgamation, such commitment to be on terms
        and conditions satisfactory to Holdco, acting reasonably;"


<PAGE>   2
                                     - 2 -


2.      The Amalgamation Agreement is hereby amended by deleting Section 18(h)
and replacing it with the following provision:

        "(h)    not later than the second Business Day immediately before the
        Effective Date, Holdco will provide the Corporation with evidence
        satisfactory to the Corporation, acting reasonably, of Holdco's ability
        to meet the condition described in Section (i); and"

3.      The amendments described in Section 1 and Section 2 above, will have the
same force and effect as if originally contained in the Amalgamation Agreement.

4.      In all other respects the terms and conditions of the Amalgamation
Agreement are hereby confirmed as being in full force and effect.


IN WITNESS WHEREOF the parties have caused this agreement to be executed as of
the date first above written.

ACCEL FINANCIAL GROUP LTD.

By: BJ Buan
   ----------------------------------
    Name

802685 ALBERTA LTD.

By: Paul B. Luke
   ----------------------------------
    Name

T&W FINANCIAL SERVICES COMPANY, L.L.C.

By: Paul B. Luke
   ----------------------------------
    Name
I 

118TH CONGRESS 

2D SESSION H. R. 7300 

To amend title V of the Social Security Act to extend funding for the 

family-to-family health information centers. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 7, 2024 

Ms. SHERRILL (for herself and Ms. DE LA CRUZ) introduced the following 

bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend title V of the Social Security Act to extend 

funding for the family-to-family health information centers. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Family-to-Family Re5 authorization Act of 2024’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7300 IH

1 SEC. 2. FIVE-YEAR EXTENSION OF FUNDING FOR FAMILY2 TO-FAMILY HEALTH INFORMATION CENTERS. 

3 Section 501(c)(1)(A)(vii) of the Social Security Act 

4 (42 U.S.C. 701(c)(1)(A)(vii)) is amended by striking 

5 ‘‘2024’’ and inserting ‘‘2029’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
#### § 203.10 Restrictions on reimportation.

No prescription drug or drug composed wholly or partly of insulin that was manufactured in a State and exported from the United States may be reimported by anyone other than its manufacturer, except that FDA may grant permission to a person other than the manufacturer to reimport a prescription drug or insulin-containing drug if it determines that such reimportation is required for emergency medical care.
**Exhibit 32.1**

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Wayside Technology Group, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Simon F. Nynens, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 
| /s/   Simon F. Nynens                   |   |
|-----------------------------------------|--------|
| Simon   F. Nynens                       |   |
| President   and Chief Executive Officer |   |
| February 18,   2011                |   |

 

*A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by Company and furnished to the Securities and Exchange Commission or its staff upon request.*

 

----
#### § 1401.1 Purpose.

The purpose of this part is to prescribe rules, guidelines and procedures to implement the Freedom of Information Act (FOIA), as amended, 5 U.S.C. 552.
<Page>

                                                                    EXHIBIT 32.1

                  CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
                           PURSUANT TO 18 U.S.C. 1350
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

    I, John P. Saldarelli, Treasurer and Chief Financial Officer (Principal
Financial Officer) of American Property Investors, Inc., the General Partner of
American Real Estate Partners, L.P. (the 'Registrant'), certify that to the best
of my knowledge, based upon a review of the American Real Estate Partners, L.P.
Quarterly Report on Form 10-Q for the period ended June 30, 2003 of the
Registrant (the 'Report'):

        (1) The Report fully complies with the requirements of Section 13(a) or
    15(d) of the Securities Exchange Act of 1934, as amended; and

        (2) The information contained in the Report fairly presents, in all
    material respects, the financial condition and results of operations of the
    Registrant.

                                                /s/ JOHN P. SALDARELLI
                                          .....................................
                                                    JOHN P. SALDARELLI
                                          TREASURER AND CHIEF FINANCIAL OFFICER
                                            AMERICAN PROPERTY INVESTORS, INC.,
                                                  THE GENERAL PARTNER OF
                                           AMERICAN REAL ESTATE PARTNERS, L.P.

Date: August 14, 2003
§ 529.400 Chlorhexidine tablets and suspension. ( a ) *Specification.* Each tablet and each 28-milliliter syringe of suspension contain 1 gram of chlorhexidine dihydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.120 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Amount.* Place 1 or 2 tablets deep in each uterine horn; or infuse a solution of 1 tablet disolved in an appropriate amount of clean boiled water; or infuse one syringe of suspension into the uterus.
( 2 ) *Indications for use.* For prevention or treatment of metritis and vaginitis in cows and mares when caused by pathogens sensitive to chlorhexidine dihydrochloride.
( 3 ) *Limitations.* Prior to administration, remove any unattached placental membranes, any excess uterine fluid or debris, and carefully clean external genitalia. Use a clean, sterile inseminating pipette for administrating solutions and suspensions. Treatment may be repeated in 48 to 72 hours.
[43 FR 10705, Feb. 23, 1979, as amended at 79 FR 10973, Feb. 27, 2014; 81 FR 67152, Sept. 30, 2016; 84 FR 32993, July 11, 2019] Editorial Note
Editorial Note: At 79 FR 10973, Feb. 27, 2014, § 529.400 was amended by revising the section heading, however, the section heading was not provided, therefore, the amendment could not be incorporated because of an inaccurate amendatory instruction.
[Cite as Toledo Bar Assn. v. Burkholder, 126 Ohio St.3d 1232, 2010-Ohio-4256.]

TOLEDO BAR ASSOCIATION v. BURKHOLDER. 

[Cite as Toledo Bar Assn. v. Burkholder, 

126 Ohio St.3d 1232, 2010-Ohio-4256.] 

(No. 2005-2394 — Submitted August 10, 2010 — Decided August 26, 2010.) 

ON APPLICATION FOR REINSTATEMENT. 

__________________ 

{¶ 1} This cause came on for further consideration upon the filing of an 

application for reinstatement by respondent, Fred Joseph Burkholder, Attorney 

Registration No. 0014094, last known business address in Toledo, Ohio. 

{¶ 2} The court coming now to consider its orders of June 21, 2006, and 

September 17, 2008, wherein the court, pursuant to Gov.Bar R. V(6)(B)(3), 

suspended respondent for a period of six months, finds that respondent has 

substantially complied with those orders and with the provisions of Gov.Bar R. 

V(10)(A). Therefore, 

{¶ 3} It is ordered by this court that respondent is reinstated to the 

practice of law in the state of Ohio. 

{¶ 4} It is further ordered that the Clerk of this court issue certified 

copies of this order as provided for in Gov.Bar R. V(8)(D)(1), that publication be 

made as provided for in Gov.Bar R. V(8)(D)(2), and that respondent bear the 

costs of publication. 

{¶ 5} For earlier cases, see Toledo Bar Assn. v. Burkholder, 109 Ohio 

St.3d 443, 2006-Ohio-2817, 848 N.E.2d 840, and 119 Ohio St.3d 1457, 2008-

Ohio-4665, 893 N.E.2d 848. 

BROWN, C.J., and PFEIFER, LUNDBERG STRATTON, O’CONNOR,

O’DONNELL, LANZINGER, and CUPP, JJ., concur. 

______________________
List of Subsidiaries
  % Held
    
    Status
    
    Country of IncorporationDirect HoldingsProtherics Medicines Development Limited
    
    
    100
    
    
    trading
    
    England and WalesProtherics Inc.
    
    
    100
    
    
    trading
    
    U.S.A. (Delaware)Enact Pharma Limited
    
    
    100
    
    
    trading
    
    England and WalesProteus Biotechnology Limited
    
    
    100
    
    
    dormant
    
    England and WalesGenethics Limited
    
    
    76
    
    
    dormant
    
    England and WalesIndirect HoldingsProtherics UK Limited
    
    
    100
    
    
    trading
    
    England and WalesProtherics Australasia pty Limited
    
    
    100
    
    
    trading
    
    AustraliaProtherics-Utah, Inc.
    
    
    100
    
    
    trading
    
    U.S.A. (Tennessee)Protherics Services pty Limited
    
    
    100
    
    
    dormant
    
    AustraliaProtherics Salt Lake City, Inc.
    
    
    100
    
    
    trading
    
    U.S.A. (Utah)Kymed GB Limited
    
    
    100
    
    
    dormant
    
    England and WalesEnzacta R&D Limited
    
    
    99.8
    
    
    dormant
    
    England and WalesDe Montfort Biopharma Limited
    
    
    100
    
    
    dormant
    
    England and WalesEnzacta Limited
    
    
    99.8
    
    
    dormant
    
    England and WalesTAb (Wales) Limited
    
    
    100
    
    
    dormant
    
    England and WalesTAb (London) Limited
    
    
    100
    
    
    dormant
    
    England and WalesPolyclonal Antibodies Limited
    
    
    100
    
    
    dormant
    
    England and Wales